These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7714978)

  • 21. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single drug polyestradiol phosphate therapy in prostatic cancer.
    Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A
    Am J Clin Oncol; 1988; 11 Suppl 2():S101-3. PubMed ID: 3242384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
    Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
    Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
    Hedlund PO; Gustafson H; Sjögren S
    Scand J Urol Nephrol Suppl; 1980; 55():103-5. PubMed ID: 6938012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
    Carlström K; Stege R
    Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
    Aro J
    Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup.
    Johansson JE; Andersson SO; Holmberg L; Bergström R
    J Urol; 1991 Mar; 145(3):519-22; discussion 522-3. PubMed ID: 1997702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
    Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation.
    Schmidt JD; Gibbons RP; Murphy GP; Bartolucci A
    Eur Urol; 1996; 29(4):425-33. PubMed ID: 8791049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant therapy for localized prostate cancer.
    Schmidt JD; Gibbons RP; Murphy GP; Bartolucci A
    Cancer; 1993 Feb; 71(3 Suppl):1005-13. PubMed ID: 8428323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment.
    Varenhorst E; Alund G
    Urology; 1985 Apr; 25(4):354-6. PubMed ID: 3157256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group.
    Kühn MW; Weissbach L; Hinke A
    Urology; 1994 Feb; 43(2 Suppl):61-7. PubMed ID: 8116135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estramustine phosphate: metabolic aspects related to its action in prostatic cancer.
    Kadohama N; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1978 Feb; 119(2):234-9. PubMed ID: 633484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
    Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
    J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
    Mittelman A; Catane R; Murphy GP
    Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.